BioMarin Pharmaceutical announced the initiation of a Phase I trial for BMN 673, a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced hematological malignancies. A Phase I/II trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.
Bradenton Herald